(RTTNews) - Evofem Biosciences Inc. (EVFM.OB) said that Phase 3 EVOGUARD clinical trial, which evaluated EVO100 for the prevention of chlamydia and gonorrhea infection in women, did not achieve its ...
Also, by evaluating the relationship between the timing of testing for gonorrhea and chlamydia (GC/CT) and the risk of developing PID within 90 days after IUD insertion, the study fills a large gap in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results